AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Albumin
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voluven
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluven
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packed Red Blood Cells
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cells
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is \<2.2 fluids are administered.
Study NCT02701582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FloTrac Monitor
Description: FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
Study NCT02701582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FloTrac Monitor
Description: FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
Study NCT00778063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2 mcg/kg intranasally 30 minutes prior to surgery
Study NCT00778063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
Study NCT00763932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Myozyme
Description: 10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
Study NCT02027363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
Study NCT02027363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
Study NCT02640651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC-Stimulator (PLUS version)
Description: transcranial direct current stimulation
Study NCT00936494 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cold ablation inferior turbinate reduction
Description: The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
Study NCT01300559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissuelink device
Description: Tissuelink device plus Unipolar electrocautery
Study NCT04006366 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Time restricted feeding
Description: We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
Study NCT00980109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active oseltamivir
Description: Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
Study NCT00980109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
Study NCT00980109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zanamivir for inhalation
Description: Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
Study NCT00980109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for inhalation
Description: Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
Study NCT04004793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Description: Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500\~750 kcal/day) for 3 months, with \<35% as fat, >15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
Study NCT04004793 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive lifestyle intervention
Description: Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500\~750 kcal/day) for 3 months, with \<35% as fat, >15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
Study NCT04004793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
Study NCT04004793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
Study NCT02071563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CSB14
Study NCT02071563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUSF1
Study NCT02071563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SC+
Study NCT04613635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratafix
Description: Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread
Study NCT04613635 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Description: Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
Study NCT04054895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lead placed in the His-Purkinje system in order to achieve QRS shortening.
Description: Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).
Study NCT04054895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lead is placed in a tributary of the coronary sinus.
Description: Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
Study NCT03215121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One handed mask airway, switch to two hands
Description: Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds.
Study NCT03054727 — intervention group
Intervention type: OTHER
Intervention: Villalta phone score > or = to 5
Description: Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score > or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination.
Study NCT03054727 — intervention group
Intervention type: OTHER
Intervention: Villalta phone score < 5
Description: Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires.
Study NCT02770287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Freeze Diamond Polar
Description: The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
Study NCT02017249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine in powder form
Study NCT02017249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Silica and cellulose placebo powder
Study NCT02795767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered as per the schedule specified in the respective arm.
Study NCT03215121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two handed mask airway + jaw thrust
Description: Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds.
Study NCT03215121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two handed mask airway, switch to one hand
Description: Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds.
Study NCT02564055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% Cream
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study NCT02564055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 0.5% Cream
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study NCT02564055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: White to off-white vehicle cream base to be applied topically
Study NCT03950219 — intervention group
Intervention type: OTHER
Intervention: Group course
Description: Education and support
Study NCT04420689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALM-488
Description: ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
Study NCT04592536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865 High dose
Description: High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
Study NCT04592536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam 1mg XR
Description: Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
Study NCT04592536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)
Study NCT04592536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865 low dose
Description: Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
Study NCT03371186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
Study NCT03371186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Surveillance
Description: Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
Study NCT03371186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CB-Integrated Management of Newborn and Childhood Illness
Description: Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
Study NCT01348919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-18770
Description: CEP-18770 will be administered per dose and schedule specified in the arm description.
Study NCT03371186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Antenatal and Postnatal Care
Description: The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
Study NCT00467142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00467142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT01348919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered per dose and schedule specified in the arm description.
Study NCT03371186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced Post-Partum Contraceptive Counseling
Description: Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
Study NCT02679729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
Study NCT01348919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered per dose and schedule specified in the arm description.
Study NCT00715897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
Study NCT02679729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for infusion
Description: Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
Study NCT02679729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance
Study NCT03999645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early laparoscopic cholecystectomy
Description: within 72h from symptom onset
Study NCT03999645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late laparoscopic cholecystectomy
Description: after 72h up to seven days from symptom onset
Study NCT00467142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride